Commentary

Podcast

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients.

This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit: kitsawet | stock.adobe.com
Related Content
HRT Hormone Therapy sign surrounded by plants and hormone therapy pills | Image Credit: © tilialucida - stock.adobe.com
July 2nd 2025

Study Links Specific Hormone Therapies to Breast Cancer Risk in Younger Women

Alexandra Gerlach, Associate Editor
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
July 1st 2025

An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Microscopic view of bone marrow slide feature are suggestive Multiple myeloma, also known as myeloma, is a type of bone marrow cancer.
Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma

Luke Halpern, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Destruction of lymphoblasts. Conceptual 3D illustration of treatment of acute lymphoblastic leukemia - Image credit: Dr_Microbe | stock.adobe.com
July 1st 2025

ASCO 2025: Age-Related Differences in Relapsed/Refractory ALL Treatment Outcomes

Kennedy Ferruggia, Assistant Editor
Group of women holding breast cancer ribbon | Image Credit: © Rawpixel.com - stock.adobe.com
July 1st 2025

Study Reveals Alarming Gaps in HER2 Therapy Access for Patients With Breast Cancer

Alexandra Gerlach, Associate Editor